Navigation Links
Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Date:5/15/2008

Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile,

with Low Incidence of Grade 3 and 4 Neuropathy

WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

"The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy," said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. "The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine."

About Study 211

Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients receiv
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
2. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
3. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
8. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
9. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... Canada, Key Trends and Opportunities to 2017 ... Synopsis The report provides in ... the Canadian personal accident and health insurance ...
(Date:8/20/2014)... , Aug. 20, 2014 Children ... can receive vaccinations to help prevent disease. The ... vaccination for all adults, but currently, many adults ... August is National Immunization Awareness Month, and the ... urging adults, especially those with lung disease, to ...
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that ... in its catalogue: Wireless Opportunities ... Zigbee, UWB WWAN, WMAN, WLAN and other ... Kalorama Information,s Wireless Opportunities in ... UWB WWAN, WMAN, WLAN and other technologies) ...
Breaking Medicine Technology:Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 3Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 4Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 5Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 7Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 8Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 9Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 10Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 11Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 12Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 13Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 14Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 15Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 16Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 17Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 18Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 19Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 20Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 21Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 22Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 23American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12
... , , , , ... Aug. 17 The US Food and Drug Administration (FDA) has approved ... sclerosis (MS) medicines from Novartis to help patients manage this devastating disease. ... for the treatment of relapsing forms of MS to reduce the frequency ...
... WA and VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... the first patient has been dosed in an open ... administered directly into the bladder in patients with bladder ... 1 trial of OGX-427 administered systemically in patients with ...
Cached Medicine Technology:US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 2US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 3US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 5US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 6US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 7OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 2OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 3OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 4
(Date:8/20/2014)... By Dennis Thompson ... -- A new experimental drug has saved a group of ... of Ebola virus that kills up to 90 percent of ... monkeys infected with lethal doses of Marburg virus, even when ... study published Aug. 20 in the journal Science Translational ...
(Date:8/20/2014)... discovered that the immune system is defective in people suffering ... sufferers have ongoing issues with pain. , The research ... also help to explain why some painkillers may not offer ... up to 10% of the community. There are different ... pain, which often has the greatest impact on sufferers, quality ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 Hundreds ... on behalf of women who were allegedly injured due ... forward in New Jersey’s Bergen County Superior Court, Bernstein ... issued on August 15, 2014, the Court has established ... for Mirena lawsuits that are part of the proceeding’s ...
(Date:8/20/2014)... 2014 (HealthDay News) -- Loss of brain cells that ... many seniors have trouble falling and staying asleep, a ... can be especially severe and often results in nighttime ... investigators analyzed data from the Rush Memory and Aging ... age 65 and are being followed until death, at ...
(Date:8/20/2014)... By Kathleen Doheny ... -- Breast reconstruction after a mastectomy has long been an ... percent of women choose it. "The most common reasons ... important, they weren,t interested in more surgery or they were ... Morrow, chief of breast surgery at Memorial Sloan Kettering Cancer ...
Breaking Medicine News(10 mins):Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:Pain treatments less effective for those with irritable bowel 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3
... , FRIDAY, Oct. 29 (HealthDay News) -- ... serious and chronic bouts of constipation, according to experts. ... consumption of water may be contributing to the problem, ... reported seeing a 30 percent rise in the number ...
... disease is being investigated in research led at the ... Trypanosomiasis, also known as sleeping sickness, affects between 50,000 ... is transmitted through the bite of the tsetse fly ... fever, headaches and disturbed sleep patterns. Without treatment, ...
... kidney failure patients in the United States are twice as likely ... although the likelihood is still low, a new studyfinds. About ... and 48 percent of them are 60 or older. The ... of the American Society of Nephrology , included kidney failure patients, ...
... GABLES, FL (October 28, 2010)To help unravel the mysteries ... in robotics, University of Miami (UM) developmental psychologists and ... Diego (UC San Diego) are studying infant-mother interactions and ... capable of learning social skills. The first phase ...
... from Mount Sinai School of Medicine have identified a ... to DNA during embryonic development and may function to ... modified by a small molecule called a phosphate, it ... signals during development. This discovery identifies a new diagnostic ...
... Oct. 28 (HealthDay News) -- The rate of new cases ... diabetes fell 35 percent between 1996 and 2007, a new ... disease, also known as end-stage renal disease (ESRD), that was ... 100,000 people during that time. The declining rates occurred in ...
Cached Medicine News:Health News:Chronic Constipation Appears to Be Increasing Among Kids 2Health News:UM researchers are studying child-mother interactions to design robots with social skills 2Health News:Newly discovered regulatory mechanism essential for embryo development and may contribute to cancer 2Health News:Drop Seen in Rate of End-Stage Kidney Disease in Diabetics 2
... utilizes a patented hands-free automatic alignment system, ... take an accurate IOP measurement in seconds. ... to the left or right and invites ... the comfortable headrest pad. The AT555 automatically ...
... perimeter that delivers optimal results even in ... more than the Easyfield. Finally, a compact ... and kinetic perimetry in a 36 visual ... shift. Offers white /white and blue /yellow ...
... Topcon KR-9000PW Wavefront Analyzer provides the ... complete visual analysis system on the ... full range auto refractometer, auto keratometer, ... adding the benefits of wavefront measurement!, ...
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
Medicine Products: